Evidence map›Paper›PMID 29652256›Full record

ArticleActa crystallographica. Section D, Structural biology2018

Exploiting distant homologues for phasing through the generation of compact fragments, local fold refinement and partial solution combination.

Claudia Millán, Massimo Domenico Sammito, Airlie J McCoy, Andrey F Ziem Nascimento, Giovanna Petrillo, Robert D Oeffner, Teresa Domínguez-Gil, Juan A Hermoso, Randy J Read, Isabel Usón

Abstract read
In one paragraph

Article in Acta crystallographica. Section D, Structural biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Scotty: lattice coincidences for macromolecular crystallographic phasing.Acta crystallographica. Section D, Structural biology · 2026
    Article
  2. ARCIMBOLDO at low resolution: Verification for coiled coils and globular proteins.Protein science : a publication of the Protein Society · 2024
    Article
  3. Article
  4. Modes and model building in SHELXE.Acta crystallographica. Section D, Structural biology · 2024
    Article
  5. Journal of applied crystallography · 2023
    Article
  6. Predicted models and CCP4.Acta crystallographica. Section D, Structural biology · 2023
    Article
  7. Fragment-BasedACS bio & med chem Au · 2023
    Article
  8. Article
  9. Verification: model-free phasing with enhanced predicted models in ARCIMBOLDO_SHREDDER.Acta crystallographica. Section D, Structural biology · 2022
    Article
  10. Article
  11. Implications of AlphaFold2 for crystallographic phasing by molecular replacement.Acta crystallographica. Section D, Structural biology · 2022
    Review
  12. Phasertng: directed acyclic graphs for crystallographic phasing.Acta crystallographica. Section D, Structural biology · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. ALIXE: a phase-combination tool for fragment-based molecular replacement.Acta crystallographica. Section D, Structural biology · 2020
    Article
  17. Article
  18. Identification of the active site residues in ATP-citrate lyase's carboxy-terminal portion.Protein science : a publication of the Protein Society · 2019
    Article
  19. Ega3 from the fungal pathogenThe Journal of biological chemistry · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Claudia MillánCrystallographic Methods, Institute of Molecular Biology of Barcelona (IBMB-CSIC), Barcelona Science Park, Helix Building, Baldiri Reixac 15, 08028 Barcelona, Spain.ORCID 0000-0002-9283-2220
Massimo Domenico SammitoDepartment of Structural Chemistry, Georg August University of Göttingen, Tammannstrasse 4, 37077 Göttingen, Germany.
Airlie J McCoyCambridge Institute for Medical Research, University of Cambridge, Hills Road, Cambridge CB2 OXY, England.
Andrey F Ziem NascimentoCrystallographic Methods, Institute of Molecular Biology of Barcelona (IBMB-CSIC), Barcelona Science Park, Helix Building, Baldiri Reixac 15, 08028 Barcelona, Spain.
Giovanna PetrilloCrystallographic Methods, Institute of Molecular Biology of Barcelona (IBMB-CSIC), Barcelona Science Park, Helix Building, Baldiri Reixac 15, 08028 Barcelona, Spain.
Robert D OeffnerCambridge Institute for Medical Research, University of Cambridge, Hills Road, Cambridge CB2 OXY, England.ORCID 0000-0003-3107-2202
Teresa Domínguez-GilDepartment of Crystallography and Structural Biology, Instituto Química-Física `Rocasolano' CSIC (Spanish National Research Council), Serrano 119, 28006 Madrid, Spain.
Juan A HermosoDepartment of Crystallography and Structural Biology, Instituto Química-Física `Rocasolano' CSIC (Spanish National Research Council), Serrano 119, 28006 Madrid, Spain.
Randy J ReadCambridge Institute for Medical Research, University of Cambridge, Hills Road, Cambridge CB2 OXY, England.ORCID 0000-0001-8273-0047
Isabel UsónCrystallographic Methods, Institute of Molecular Biology of Barcelona (IBMB-CSIC), Barcelona Science Park, Helix Building, Baldiri Reixac 15, 08028 Barcelona, Spain.

Funding

PROJECT 5 - DUKE - STRUCTURE VALIDATION AND IMPROVEMENT FOR PROTEINS AND N. ACIDSP01GM063210 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI ADAMS, PAUL DAVID · 2001 to 2021
$33.5M
Biotechnology and Biological Sciences Research Council BB/L006014/1NIGMS NIH HHS P01 GM063210Wellcome Trust 082961/Z/07/ZWellcome Trust 209407/Z/17/Z
6 · The paper itself

Abstract

Macromolecular structures can be solved by molecular replacement provided that suitable search models are available. Models from distant homologues may deviate too much from the target structure to succeed, notwithstanding an overall similar fold or even their featuring areas of very close geometry. Successful methods to make the most of such templates usually rely on the degree of conservation to select and improve search models. ARCIMBOLDO_SHREDDER uses fragments derived from distant homologues in a brute-force approach driven by the experimental data, instead of by sequence similarity. The new algorithms implemented in ARCIMBOLDO_SHREDDER are described in detail, illustrating its characteristic aspects in the solution of new and test structures. In an advance from the previously published algorithm, which was based on omitting or extracting contiguous polypeptide spans, model generation now uses three-dimensional volumes respecting structural units. The optimal fragment size is estimated from the expected log-likelihood gain (LLG) values computed assuming that a substructure can be found with a level of accuracy near that required for successful extension of the structure, typically below 0.6 Å root-mean-square deviation (r.m.s.d.) from the target. Better sampling is attempted through model trimming or decomposition into rigid groups and optimization through Phaser's gyre refinement. Also, after model translation, packing filtering and refinement, models are either disassembled into predetermined rigid groups and refined (gimble refinement) or Phaser's LLG-guided pruning is used to trim the model of residues that are not contributing signal to the LLG at the target r.m.s.d. value. Phase combination among consistent partial solutions is performed in reciprocal space with ALIXE. Finally, density modification and main-chain autotracing in SHELXE serve to expand to the full structure and identify successful solutions. The performance on test data and the solution of new structures are described.

Indexed as

AlgorithmsModels, MolecularStructural Homology, ProteinBacterial ProteinsComputer SimulationCrystallography, X-RayMacromolecular SubstancesBacterial ProteinsMacromolecular SubstancesARCIMBOLDO_SHREDDERfragment-based molecular replacementmolecular replacementphasingsmall fragments

Identifiers

PMID29652256
PMCPMC5892878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.